News Release 

Risk of target organ damage in patients with masked hypertension versus sustained hypertension

Compuscript Ltd

Research News

In a new publication from Cardiovascular Innovations and Applications; DOI https://doi.org/10.15212/CVIA.2019.1261, Yue Wu, Guoyue Zhang, Rong Hu and Jianlin Du from The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China consider the risk of target organ damage in patients with masked hypertension versus sustained hypertension.

The authors compared the risk of target organ damage in masked hypertension (MH) and sustained hypertension (SH) through a systematic review and meta-analysis of PubMed, Embase, and the Cochrane Library of relevant case-control studies. Articles on MH and SH were selected according to the inclusion criteria and were analyzed. The primary end point was target organ damage in the heart. The secondary end points were target organ damage in the kidneys and blood vessels.

Seventeen studies that met the screening criteria were included in the meta-analysis. Compared with the SH group, in the MH group carotid intima-media thickness (IMT) and E/A ratio were significantly greater and the prevalence of left ventricular remodeling and the pulse wave velocity were significantly lower. Other indicators in the heart, kidneys, and blood vessels were not statistically different between the two groups. IMT: P=0.01, E/A ratio: P=0.01, prevalence of left ventricular remodeling: P=0.02, pulse wave velocity: P=0.01.

The study shows that MH may have almost the same degree of target organ damage as SH, so clinicians may need to consider target organ damage.

###

Citation information: Risk of Target Organ Damage in Patients with Masked Hypertension versus Sustained Hypertension: A Meta-analysis, Yue Wu, Guoyue Zhang, Rong Hu, Jianlin Du, Cardiovasc. Innov. App., 2020, https://doi.org/10.15212/CVIA.2019.1261

Keywords: masked hypertension; sustained hypertension; target organ; meta-analysis

CVIA is available on the IngentaConnect platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. CVIA is indexed in the EMBASE, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ and Index Copernicus Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.